Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes

DNA glycation, a non-enzymatic modification triggered by reactive metabolites such as methylglyoxal (MG), has been implicated in various metabolic and neurological disorders. However, its genome-wide distribution and biological consequences in the developing brain remain largely unexplored. To address this gap, we developed a novel method, GlyDIP-seq, which enables high-resolution profiling of glycation-derived DNA lesions (specifically N²-carboxyethyl-2'-deoxyguanosine, CEdG) across the genome.